# Merus N.V. (MRUS)

Source: https://www.quantisnow.com/company/MRUS
Generated: 2026-11-12T18:20:38.033Z

- Ticker: MRUS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016
- Website: merus.nl

## About

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

## Latest MRUS news and filings

- 2026-08-14 20:05 UTC [Leadership Update] [LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/leonabio-reports-second-quarter-2026-financial-results-and-provides-business-6682952)
- 2026-05-12 08:49 UTC [FDA Approval for BIZENGRI issued to MERUS N.V.](https://www.quantisnow.com/insight/fda-approval-for-bizengri-issued-to-merus-nv-6546319)
- 2026-05-11 20:51 UTC [FDA Approval for BIZENGRI issued to MERUS N.V.](https://www.quantisnow.com/insight/fda-approval-for-bizengri-issued-to-merus-nv-6545611)
- 2026-05-07 20:05 UTC [Leadership Update] [LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/leonabio-reports-first-quarter-2026-financial-results-and-provides-business-6538850)
- 2026-05-07 13:20 UTC [Leadership Update] [LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.](https://www.quantisnow.com/insight/leonabio-enhances-board-of-directors-with-appointments-of-fred-callori-6537998)
- 2026-02-11 22:31 UTC [EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight](https://www.quantisnow.com/insight/egfr-nsclc-market-to-observe-stunning-growth-at-a-cagr-of-6387446)
- 2026-01-09 11:15 UTC [SEC Form 15-12G filed by Merus N.V.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-merus-nv-6343755)
- 2025-12-30 22:24 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Merus N.V.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-merus-nv-6330251)
- 2025-12-30 14:04 UTC [Amendment: SEC Form 25-NSE/A filed by Merus N.V.](https://www.quantisnow.com/insight/amendment-sec-form-25-nsea-filed-by-merus-nv-6329523)
- 2025-12-30 13:32 UTC [SEC Form 8-K] [Merus N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders](https://www.quantisnow.com/insight/merus-nv-filed-sec-form-8-k-completion-of-acquisition-or-6329480)
- 2025-12-30 13:09 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Merus N.V.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-merus-nv-6329448)
- 2025-12-30 12:52 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Merus N.V.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-merus-nv-6329395)
- 2025-12-29 22:16 UTC [Insider Buy] [Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-genmab-as-bought-79098068-worth-of-shares-815444-6328967)
- 2025-12-22 22:15 UTC [Insider Buy] [Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-genmab-as-bought-27008777-worth-of-shares-278441-6325799)
- 2025-12-19 17:32 UTC [SEC Form SCHEDULE 13D filed by Merus N.V.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-merus-nv-6323441)
- 2025-12-18 22:54 UTC [Insider Buy] [Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-genmab-as-bought-26340059-worth-of-shares-271547-6322736)
- 2025-12-16 18:17 UTC [Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B](https://www.quantisnow.com/insight/immunotherapy-breakthroughs-turn-cold-gi-tumors-hot-as-market-tops-6317705)
- 2025-12-13 00:09 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer & PFO Perry Gregory D](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-pfo-perry-6314923)
- 2025-12-13 00:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Mehra Anand](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mehra-anand-6314913)
- 2025-12-13 00:04 UTC [SEC Form 4] [SEC Form 4 filed by Director Kanavy Len](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kanavy-len-6314912)
- 2025-12-13 00:02 UTC [SEC Form 4] [SEC Form 4 filed by Director Haddock Jason](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-haddock-jason-6314908)
- 2025-12-13 00:02 UTC [SEC Form 4] [SEC Form 4 filed by COO & GC Silverman Peter B.](https://www.quantisnow.com/insight/sec-form-4-filed-by-coo-gc-silverman-peter-b-6314907)
- 2025-12-13 00:00 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Zohren Fabian](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-zohren-fabian-6314895)
- 2025-12-12 23:59 UTC [SEC Form 4] [SEC Form 4 filed by President, CEO & PEO Lundberg Sven Ante](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-ceo-peo-lundberg-sven-6314892)
- 2025-12-12 23:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Pucci Paolo](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-pucci-paolo-6314887)
- 2025-12-12 23:55 UTC [SEC Form 4] [VP Controller, PAO Shuman Harry closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/vp-controller-pao-shuman-harry-closing-all-direct-ownership-in-6314886)
- 2025-12-12 23:54 UTC [SEC Form 4] [SEC Form 4 filed by Director Sandor Victor](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sandor-victor-6314885)
- 2025-12-12 23:52 UTC [SEC Form 4] [Director Iwicki Mark T closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-iwicki-mark-t-closing-all-direct-ownership-in-the-6314883)
- 2025-12-12 23:49 UTC [SEC Form 4] [SEC Form 4 filed by Director Gowen Maxine](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gowen-maxine-6314876)
- 2025-12-12 13:02 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Merus N.V.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-merus-nv-6313414)
- 2025-12-12 13:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Merus N.V.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-merus-nv-6313410)
- 2025-12-12 13:00 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Merus N.V.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-merus-nv-6313405)
- 2025-12-12 12:59 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Merus N.V.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-merus-nv-6313381)
- 2025-12-12 12:56 UTC [SEC Form POSASR filed by Merus N.V.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-merus-nv-6313380)
- 2025-12-12 12:54 UTC [SEC Form 8-K] [Merus N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Leadership Update](https://www.quantisnow.com/insight/merus-nv-filed-sec-form-8-k-completion-of-acquisition-or-6313379)
- 2025-12-12 12:52 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Merus N.V.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-merus-nv-6313376)
- 2025-12-12 12:45 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Merus N.V.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-merus-nv-6313373)
- 2025-12-12 06:36 UTC [Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period](https://www.quantisnow.com/insight/genmab-announces-completion-of-tender-offer-for-outstanding-common-shares-6313234)
- 2025-12-12 06:35 UTC [Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period](https://www.quantisnow.com/insight/genmab-announces-completion-of-tender-offer-for-outstanding-common-shares-6313233)
- 2025-12-10 22:45 UTC [SEC Form 4] [VP Controller, PAO Shuman Harry sold $163,370 worth of shares (1,700 units at $96.10) and exercised 1,700 shares at a strike of $21.69 (SEC Form 4)](https://www.quantisnow.com/insight/vp-controller-pao-shuman-harry-sold-163370-worth-of-shares-6311130)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MRUS
- Earnings history: https://www.quantisnow.com/earnings/MRUS
- Dividend history: https://www.quantisnow.com/dividends/MRUS
- Insider transactions: https://www.quantisnow.com/insiders/MRUS
- Options chain: https://www.quantisnow.com/options/MRUS
- SEC 8-K filings only: https://www.quantisnow.com/company/MRUS/8-k
- RSS and alerts for MRUS: https://www.quantisnow.com/docs/rss-feeds.md